Skip to main content
Fig. 3 | Radiation Oncology

Fig. 3

From: Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients

Fig. 3

Kaplan–Meier curve displaying limited overall survival in all patients. A Progression free survival for all 40 patients evaluated; B Overall survival for all 40 patients evaluated; C The median PFS was 7 months (range 1.1–12.9 months) and 12 months (range NA) for PD-L1 negative and positive group respectively (p = 0.059); D OS had no statistical significance in PD-L1 negative and positive group (19 vs 20 months, p = 0.968) (Fig. 3D)

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us